of New Hampshire's request to revise its part 142—National Primary Drinking Water Regulations Implementation program to allow electronic reporting will become effective 30 days after this notice is published, pursuant to CROMERR section 3.1000(f)(4).

Dated: May 3, 2021.

Jennifer Campbell,

Director, Office of Information Management. [FR Doc. 2021–09793 Filed 5–7–21; 8:45 am]

BILLING CODE 6560-50-P

## FEDERAL DEPOSIT INSURANCE CORPORATION

### **Notice of Termination of Receiverships**

The Federal Deposit Insurance Corporation (FDIC or Receiver), as Receiver for each of the following insured depository institutions, was charged with the duty of winding up the affairs of the former institutions and liquidating all related assets. The Receiver has fulfilled its obligations and made all dividend distributions required by law.

#### NOTICE OF TERMINATION OF RECEIVERSHIPS

| Fund                                      | Receivership name      | City                                                | State                            | Termination date                                                                               |
|-------------------------------------------|------------------------|-----------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------|
| 10313<br>10353<br>10371<br>10377<br>10419 | Tifton Banking Company | Tifton Cartersville Jackson Stockbridge Stockbridge | AZ<br>GA<br>GA<br>GA<br>GA<br>GA | 05/01/2021<br>05/01/2021<br>05/01/2021<br>05/01/2021<br>05/01/2021<br>05/01/2021<br>05/01/2021 |

The Receiver has further irrevocably authorized and appointed FDIC-Corporate as its attorney-in-fact to execute and file any and all documents that may be required to be executed by the Receiver which FDIC-Corporate, in its sole discretion, deems necessary, including but not limited to releases, discharges, satisfactions, endorsements, assignments, and deeds. Effective on the termination dates listed above, the Receiverships have been terminated, the Receiverships have ceased to exist as legal entities.

(Authority: 12 U.S.C. 1819)

Federal Deposit Insurance Corporation.

Dated at Washington, DC, on May 5, 2021.

#### Debra A. Decker,

Deputy Executive Secretary. [FR Doc. 2021–09868 Filed 5–7–21; 8:45 am]

BILLING CODE 6714-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

## Conditional Sailing Order Technical Instructions and Operations Manual

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), announces the availability of additional technical instructions and documents released under its Framework for Conditional Sailing Order (CSO). These documents apply to cruise ship operators with cruise ships operating in U.S. waters and cruise ship operators who are operating cruise ships outside of U.S. waters, but intend for their cruise ships to return to operating in U.S. waters while CDC's Conditional Sailing Order remains in effect.

**DATES:** These documents were available April 2, 2021 and May 5, 2021.

### FOR FURTHER INFORMATION CONTACT:

Jennifer Buigut, Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H16–4, Atlanta, GA 30329. Phone: 404–498–1600. Email: dgmqpolicyoffice@cdc.gov.

### SUPPLEMENTARY INFORMATION: On

October 30, 2020 CDC issued an Agency Order establishing a framework for a phased approach to resuming cruise ship passenger operations in U.S. waters (85 FR 70153). The phased approach includes: (1) Establishment of laboratory testing of crew onboard cruise ships in U.S. waters; (2) simulated voyages designed to test a cruise ship operators' ability to mitigate COVID-19 onboard cruise ships; (3) a certification process; and (4) a return to passenger voyages in a manner that mitigates the risk of COVID-19 introduction, transmission, or spread among passengers and crew onboard ships and ashore to communities.

In the initial crew testing phase, the Order additionally contained requirements for: (1) Shoreside COVID—19 laboratory screening testing of all crew currently onboard cruise ships; (2) onboard diagnostic testing capabilities for symptomatic travelers (crew and future passengers); (3) shoreside COVID—19 laboratory screening testing of all newly embarking crew; and (4) continued compliance with complete, accurate, and acknowledged, No Sail Order Response Plans.

On April 2, 2021 CDC released Phase 2A Technical Instructions. Phase 2A Technical Instructions assists cruise ship operators in documenting the approval of U.S. port and local health authorities as a condition of receiving or retaining controlled free pratique to conduct a simulated voyage or to obtain a COVID-19 Conditional Sailing Certificate to commence restricted passenger voyages. This includes documenting the approval of U.S. port and local health authorities in developing medical care, housing, and port components (including a vaccination component).

On May 5, 2021 CDC released two documents under Phase 2B and Phase 3 of the Conditional Sailing Framework: Technical Instructions for Simulated Voyages by Cruise Ship Operators under CDC's Framework for Conditional Sailing Order and COVID–19 Operations Manual for Simulated and Restricted Voyages under the Framework for Conditional Sailing Order.

The Technical Instructions for Simulated Voyages provides technical instructions for Phase 2B of CDC's CSO for cruise ship operators to test the efficacy of their health and safety protocols in U.S. waters. In lieu of conducting a simulated voyage, a cruise ship operator's responsible officials, at their discretion, may sign and submit to CDC an attestation under 18 U.S.C. 1001 that 98 percent of crew are fully vaccinated and submit to CDC a clear and specific vaccination plan and timeline to limit cruise ship sailings to 95 percent of passengers who have been verified by the cruise ship operator as fully vaccinated prior to sailing.

CDC's oversight and inspection of cruise ships during simulated and restricted passenger voyages will be based on the Operations Manual. The findings and/or observations of these inspections will be shared with the cruise ship operator. Cruise ship operators are expected to align their health and safety protocols with any CDC findings and observations. Such findings and observations must also be incorporated into the cruise ship operator's simulated voyage after-action report or as a condition of applying for and retaining permission to conduct restricted passenger voyages. Based on these inspections, CDC may also issue additional recommendations to the cruise ship operator that the operator should consider for adoption into their health and safety protocols as best practices.

The Technical Instructions document for Cruise Ship Operator's Agreement with Port and Local Health Authorities under CDC's Framework for Conditional Sailing Order is found at <a href="https://www.cdc.gov/quarantine/cruise/instructions-local-agreements.html">https://www.cdc.gov/quarantine/cruise/instructions-local-agreements.html</a>.

The Technical Instructions document for Simulated Voyages by Cruise Ship Operators under CDC's Framework for Conditional Sailing Order is found at https://www.cdc.gov/quarantine/cruise/ti-simulated-voyages-cso.html.

The COVID—19 Operations Manual for Simulated and Restricted Voyages under the Framework for Conditional Sailing Order is found at https://www.cdc.gov/quarantine/cruise/covid19-operations-manual-cso.html.

#### Authority

The Technical Instructions and Operations Manual are issued pursuant to the Framework for Conditional Sailing which was issued under the authority of Sections 361 and 365 of the Public Health Service Act (42 U.S.C. 264, 268) and 42 CFR 70.2, 71.31(b), 71.32(b).

Dated: May 5, 2021.

#### Sherri Berger,

Acting Chief of Staff, Centers for Disease Control and Prevention.

[FR Doc. 2021–09895 Filed 5–6–21; 4:15 pm]

BILLING CODE 4163-18-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

[Docket No. CDC-2021-0049]

# Advisory Committee on Immunization Practices (ACIP)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. The meeting will be webcast live via the World Wide Web.

**DATES:** The meeting will be held on May 12, 2021, from 11:00 a.m. to 5:00 p.m., EDT (dates and times subject to change, see the ACIP website for updates: http://www.cdc.gov/vaccines/acip/index.html). The public may submit comments from May 10, 2021 through May 12, 2021.

**ADDRESSES:** For more information on ACIP please visit the ACIP website: http://www.cdc.gov/vaccines/acip/index.html.

You may submit comments, identified by Docket No. CDC-2021-0049 by any of the following methods:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.
- *Mail*: Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-H24-8, Atlanta, GA 30329-4027, Attn: May 12, 2021 ACIP Meeting.

Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov.

**FOR FURTHER INFORMATION CONTACT:** Stephanie Thomas, ACIP Committee

Management Specialist, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS–H24–8, Atlanta, GA 30329–4027; Telephone: 404–639–8367; Email: ACIP@cdc.gov.

SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less than 15 calendar days' notice is being given for this meeting due to the exceptional circumstances of the COVID-19 pandemic and rapidly evolving COVID-19 vaccine development and regulatory processes. The Secretary of Health and Human Services has determined that COVID-19 is a Public Health Emergency. A notice of this ACIP meeting has also been posted on CDC's ACIP website at: http:// www.cdc.gov/vaccines/acip/index.html. In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP.

Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

Matters to be Considered: The agenda will include discussions on COVID–19 vaccines, including use of the Pfizer-BioNTech COVID–19 vaccine under the Food and Drug Administration's (FDA) expanded Emergency Use Authorization (EUA) for adolescents 12–15 years of age. A recommendation vote(s) is scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.

Meeting Information: The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: http://www.cdc.gov/vaccines/acip/index.html.

#### **Public Participation**

Interested persons or organizations are invited to participate by submitting written views, recommendations, and